Improving the translation of animal ischemic stroke studies to humans

Metabolic Brain Disease

Volumn 30, Issue 2, 2015, Pages 461-467

  Jickling, Glen C ^a   Sharp, Frank R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; Cerebrovascular disease; Clinical trial; Stroke

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL; BRAIN ISCHEMIA; DISEASE MODEL; HUMAN; MOUSE; PATHOLOGY; SPECIES DIFFERENCE; STROKE; TRANSLATIONAL RESEARCH;

ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HUMANS; MICE; SPECIES SPECIFICITY; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84893700628     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-014-9499-2     Document Type: Article

References (70)

1. Abou-Chebl A, Lin R, Hussain MS, Jovin TG, Levy EI, Liebeskind DS, Yoo AJ, Hsu DP, Rymer MM, Tayal AH, Zaidat OO, Natarajan SK, Nogueira RG, Nanda A, Tian M, Hao Q, Kalia JS, Nguyen TN, Chen M, Gupta R (2010) Conscious sedation versus general anesthesia during endovascular therapy for acute anterior circulation stroke: preliminary results from a retrospective, multicenter study. Stroke J Cereb Circ 41(6):1175–1179. doi:10.1161/STROKEAHA.109.574129
2. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, Hurn P, Liebeskind DS, Nogueira RG, Saver JL, Consortium SV (2011) Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke J Cereb Circ 42(9):2645–2650. doi:10.1161/STROKEAHA.111.618850
3. Bailey EL, McCulloch J, Sudlow C, Wardlaw JM (2009) Potential animal models of lacunar stroke: a systematic review. Stroke J Cereb Circ 40(6):e451–e458. doi:10.1161/STROKEAHA.108.528430
4. Bailey EL, Smith C, Sudlow CL, Wardlaw JM (2011a) Is the spontaneously hypertensive stroke prone rat a pertinent model of sub cortical ischemic stroke? A systematic review. Int J Stroke Off J Int Stroke Soc 6(5):434–444. doi:10.1111/j.1747-4949.2011.00659.x
5. Bailey EL, Wardlaw JM, Graham D, Dominiczak AF, Sudlow CL, Smith C (2011b) Cerebral small vessel endothelial structural changes predate hypertension in stroke-prone spontaneously hypertensive rats: a blinded, controlled immunohistochemical study of 5- to 21-week-old rats. Neuropathol Appl Neurobiol 37(7):711–726. doi:10.1111/j.1365-2990.2011.01170.x
6. Banks JL, Marotta CA (2007) Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke J Cereb Circ 38(3):1091–1096. doi:10.1161/01.STR.0000258355.23810.c6
7. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD (1996) Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke J Cereb Circ 27(9):1616–1622, discussion 1623
8. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA, Interventional Management of Stroke IIII (2013) Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. New Engl J Med 368(10):893–903. doi:10.1056/NEJMoa1214300
9. Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J (2001) Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke J Cereb Circ 32(3):748–752
10. Daugherty A, Lu H, Howatt DA, Rateri DL (2009) Modes of defining atherosclerosis in mouse models: relative merits and evolving standards. Methods Mol Biol 573:1–15. doi:10.1007/978-1-60761-247-6_1
11. Davis MJ, Menon BK, Baghirzada LB, Campos-Herrera CR, Goyal M, Hill MD, Archer DP, Calgary Stroke P (2012) Anesthetic management and outcome in patients during endovascular therapy for acute stroke. Anesthesiology 116(2):396–405. doi:10.1097/ALN.0b013e318242a5d2
12. Fearon P, McArthur KS, Garrity K, Graham LJ, McGroarty G, Vincent S, Quinn TJ (2012) Prestroke modified rankin stroke scale has moderate interobserver reliability and validity in an acute stroke setting. Stroke J Cereb Circ 43(12):3184–3188. doi:10.1161/STROKEAHA.112.670422
13. Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, Finklestein SP, Pangalos MN, Poole M, Stiles GL, Ruffolo RR, Walsh FL (2008) Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 28(1):217–219. doi:10.1038/sj.jcbfm.9600516
14. Fisher M, Stroke Therapy Academic Industry R (2003) Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke J Cereb Circ 34(6):1539–1546. doi:10.1161/01.STR.0000072983.64326.53
15. Fisher M, Albers GW, Donnan GA, Furlan AJ, Grotta JC, Kidwell CS, Sacco RL, Wechsler LR, Stroke Therapy Academic Industry Roundtable IV (2005) Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. Stroke J Cereb Circ 36(8):1808–1813. doi:10.1161/01.STR.0000173403.60553.27
16. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S, Group S (2007) Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke J Cereb Circ 38(2):245–248. doi:10.1161/01.STR.0000255951.37434.aa
17. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH, Group S (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke J Cereb Circ 40(6):2244–2250. doi:10.1161/STROKEAHA.108.541128
18. Flexman AM, Donovan AL, Gelb AW (2012) Anesthetic management of patients with acute stroke. Anesthesiol Clin 30(2):175–190. doi:10.1016/j.anclin.2012.04.002
19. Fox JG (1985) Laboratory-animal medicine changes and challenges. Cornell Vet 75(1):159–170
20. Froehler MT, Fifi JT, Majid A, Bhatt A, Ouyang M, McDonagh DL (2012) Anesthesia for endovascular treatment of acute ischemic stroke. Neurology 79(13 Suppl 1):S167–S173. doi:10.1212/WNL.0b013e31826959c2
21. Gakuba C, Gauberti M, Mazighi M, Defer G, Hanouz JL, Vivien D (2011) Preclinical evidence toward the use of ketamine for recombinant tissue-type plasminogen activator-mediated thrombolysis under anesthesia or sedation. Stroke J Cereb Circ 42(10):2947–2949. doi:10.1161/STROKEAHA.111.620468
22. Gelb AW, Bayona NA, Wilson JX, Cechetto DF (2002) Propofol anesthesia compared to awake reduces infarct size in rats. Anesthesiology 96(5):1183–1190
23. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, Waldman BD, Tamariz D, Ryckborst KJ, Alias, Neurological Emergencies Treatment Trials I (2013) High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol 12(11):1049–1058. doi:10.1016/S1474-4422(13)70223-0
24. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, E Investigators (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. New Engl J Med 359(13):1317–1329. doi:10.1056/NEJMoa0804656
25. Hainsworth AH, Markus HS (2008) Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 28(12):1877–1891. doi:10.1038/jcbfm.2008.91
26. Head BP, Patel P (2007) Anesthetics and brain protection. Curr Opin Anaesthesiol 20(5):395–399
27. Henninger N, Sicard KM, Schmidt KF, Bardutzky J, Fisher M (2006) Comparison of ischemic lesion evolution in embolic versus mechanical middle cerebral artery occlusion in Sprague Dawley rats using diffusion and perfusion imaging. Stroke J Cereb Circ 37(5):1283–1287. doi:10.1161/01.STR.0000217223.72193.98
28. Hossmann KA (2012) The two pathophysiologies of focal brain ischemia: implications for translational stroke research. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 32(7):1310–1316. doi:10.1038/jcbfm.2011.186
29. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC (2003) Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology 61(1):71–75
30. Huybrechts KF, Caro JJ (2007) The Barthel Index and modified Rankin Scale as prognostic tools for long-term outcomes after stroke: a qualitative review of the literature. Curr Med Res Opin 23(7):1627–1636. doi:10.1185/030079907X210444
31. Jickling GC, Xu H, Stamova B, Ander BP, Zhan X, Tian Y, Liu D, Turner RJ, Mesias M, Verro P, Khoury J, Jauch EC, Pancioli A, Broderick JP, Sharp FR (2010) Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol 68(5):681–692. doi:10.1002/ana.22187
32. Jickling GC, Stamova B, Ander BP, Zhan X, Tian Y, Liu D, Xu H, Johnston SC, Verro P, Sharp FR (2011) Profiles of lacunar and nonlacunar stroke. Ann Neurol 70(3):477–485. doi:10.1002/ana.22497
33. Karatas H, Erdener SE, Gursoy-Ozdemir Y, Gurer G, Soylemezoglu F, Dunn AK, Dalkara T (2011) Thrombotic distal middle cerebral artery occlusion produced by topical FeCl(3) application: a novel model suitable for intravital microscopy and thrombolysis studies. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 31(6):1452–1460. doi:10.1038/jcbfm.2011.8
34. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH, Yoo AJ, Marshall RS, Meyers PM, Yavagal DR, Wintermark M, Guzy J, Starkman S, Saver JL, MR Investigators (2013) A trial of imaging selection and endovascular treatment for ischemic stroke. New Engl J Med 368(10):914–923. doi:10.1056/NEJMoa1212793
35. Kirsch JR, Traystman RJ, Hurn PD (1996) Anesthetics and cerebroprotection: experimental aspects. Int Anesthesiol Clin 34(4):73–93
36. Koerner IP, Brambrink AM (2006) Brain protection by anesthetic agents. Curr Opin Anaesthesiol 19(5):481–486
37. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490(7419):187–191. doi:10.1038/nature11556
38. Lansberg MG, Lee J, Christensen S, Straka M, De Silva DA, Mlynash M, Campbell BC, Bammer R, Olivot JM, Desmond P, Davis SM, Donnan GA, Albers GW (2011) RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Stroke J Cereb Circ 42(6):1608–1614. doi:10.1161/STROKEAHA.110.609008
39. Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG, Wilder MJ, Lutsep HL, Czartoski TJ, Bernstein RA, Chang CW, Warach S, Fazekas F, Inoue M, Tipirneni A, Hamilton SA, Zaharchuk G, Marks MP, Bammer R, Albers GW, investigators Ds (2012) MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 11(10):860–867. doi:10.1016/S1474-4422(12)70203-X
40. Lapchak PA (2009) Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model. Brain Res 1294:211–217. doi:10.1016/j.brainres.2009.07.058
41. Lapchak PA (2010) Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res 1(2):96–107. doi:10.1007/s12975-010-0018-4
42. Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA (2002a) Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke J Cereb Circ 33(9):2279–2284
43. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA (2002b) Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke J Cereb Circ 33(5):1411–1415
44. Lapchak PA, Zhang JH, Noble-Haeusslein LJ (2013) RIGOR Guidelines: Escalating STAIR and STEPS for effective translational research. Transl Stroke Res 4(3):279–285. doi:10.1007/s12975-012-0209-2
45. Liou SY, Stringer F, Hirayama M (2012) The impact of pharmacogenomics research on drug development. Drug Metab Pharmacokinet 27(1):2–8
46. Meyer DM, Compton P, Eastwood JA, Gylys K, Zivin JA (2013) Antiplatelet loading improves behavioral outcome in a rabbit model of stroke. Stroke J Cereb Circ 44(11):3246–3248. doi:10.1161/STROKEAHA.113.002565
47. O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW (2006) 1,026 experimental treatments in acute stroke. Ann Neurol 59(3):467–477. doi:10.1002/ana.20741
48. Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E, Agin V, Vivien D (2007) Mouse model of in situ thromboembolic stroke and reperfusion. Stroke J Cereb Circ 38(10):2771–2778. doi:10.1161/STROKEAHA.107.487520
49. Plenge RM, Scolnick EM, Altshuler D (2013) Validating therapeutic targets through human genetics. Nat Rev Drug Discov 12(8):581–594. doi:10.1038/nrd4051
50. Quinn TJ, Dawson J, Walters MR, Lees KR (2009) Reliability of the modified Rankin Scale: a systematic review. Stroke J Cereb Circ 40(10):3393–3395. doi:10.1161/STROKEAHA.109.557256
51. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J Off Publ Fed Am Soc Exp Biol 22(3):659–661. doi:10.1096/fj.07-9574LSF
52. Rosell A, Agin V, Rahman M, Morancho A, Ali C, Koistinaho J, Wang X, Vivien D, Schwaninger M, Montaner J (2013) Distal occlusion of the middle cerebral artery in mice: are we ready to assess long-term functional outcome? Transl Stroke Res 4(3):297–307. doi:10.1007/s12975-012-0234-1
53. Russell JC, Proctor SD (2006) Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol Off J Soc Cardiovasc Pathol 15(6):318–330. doi:10.1016/j.carpath.2006.09.001
54. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M, Consortium SV (2009) Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke J Cereb Circ 40(7):2594–2600. doi:10.1161/STROKEAHA.109.552554
55. Sicard KM, Fisher M (2009) Animal models of focal brain ischemia. Exp Transl Stroke Med 1:7–7
56. Singh SS (2006) Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Current Drug Metab 7(2):165–182
57. Stamova B, Xu H, Jickling G, Bushnell C, Tian Y, Ander BP, Zhan X, Liu D, Turner R, Adamczyk P, Khoury JC, Pancioli A, Jauch E, Broderick JP, Sharp FR (2010) Gene expression profiling of blood for the prediction of ischemic stroke. Stroke J Cereb Circ 41(10):2171–2177. doi:10.1161/STROKEAHA.110.588335
58. Stroke Therapy Academic Industry R, II (2001) Recommendations for clinical trial evaluation of acute stroke therapies. Stroke J Cereb Circ 32(7):1598–1606
59. Takano K, Tatlisumak T, Bergmann AG, Gibson DG 3rd, Fisher M (1997) Reproducibility and reliability of middle cerebral artery occlusion using a silicone-coated suture (Koizumi) in rats. J Neurol Sci 153(1):8–11
60. Tang Y, Lu A, Aronow BJ, Sharp FR (2001) Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann Neurol 50(6):699–707
61. Tang Y, Xu H, Du X, Lit L, Walker W, Lu A, Ran R, Gregg JP, Reilly M, Pancioli A, Khoury JC, Sauerbeck LR, Carrozzella JA, Spilker J, Clark J, Wagner KR, Jauch EC, Chang DJ, Verro P, Broderick JP, Sharp FR (2006) Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 26(8):1089–1102. doi:10.1038/sj.jcbfm.9600264
62. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 333(24):1581–1587. doi:10.1056/NEJM199512143332401
63. Verbeuren TJ (2006) Experimental models of thrombosis and atherosclerosis. Therapie 61(5):379–387
64. Wang L, Jing W, Hang YN (2008) Glutamate-induced c-Jun expression in neuronal PC12 cells: the effects of ketamine and propofol. J Neurosurg Anesthesiol 20(2):124–130
65. Weisscher N, Vermeulen M, Roos YB, de Haan RJ (2008) What should be defined as good outcome in stroke trials; a modified Rankin score of 0–1 or 0–2? J Neurol 255(6):867–874. doi:10.1007/s00415-008-0796-8
66. Yanni AE (2004) The laboratory rabbit: an animal model of atherosclerosis research. Lab Anim 38(3):246–256. doi:10.3201/eid0905.020321
67. Yao H, Nabika T (2012) Standards and pitfalls of focal ischemia models in spontaneously hypertensive rats: with a systematic review of recent articles. J Transl Med 10:139. doi:10.1186/1479-5876-10-139
68. Zhang GY, Chen ZQ, Ling F, Li YJ, Wang Y, Gu BX (2010) Establishment of a novel hemodynamic cerebral ischemia model of atherosclerotic rabbit. Neurol India 58(2):191–194. doi:10.4103/0028-3886.63782
69. Zhao H, Collier JM, Quah DM, Purvis T, Bernhardt J (2010) The modified Rankin Scale in acute stroke has good inter-rater-reliability but questionable validity. Cerebrovasc Dis 29(2):188–193. doi:10.1159/000267278
70. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA (1985) Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230(4731):1289–1292